Are you suffering from Knee Osteoarthritis Pain?

A detailed 3D medical illustration of a human knee joint, showing bones, cartilage, and inner structures.

Knee Osteoarthritis Pain

The purpose of this research is to learn more about the use of the experimental study medicine, pentosan polysulfate sodium (PPS), for the treatment of knee osteoarthritis pain given as an injection.

Study information:

  • Condition: Knee Osteoarthritis

  • Location: Las Vegas, Nevada

  • Duration: Up to 64 weeks

  • Participation: Up to 22 visits

  • Compensation: Up to $1425

The logo of Paradigm Biopharma with the word 'PARADIGM' in black, pink, and purple letters, and 'BIOPHARMA' in gray letters below.

Eligibility:

  • Age 18 or older

  • Diagnosis of knee osteoarthritis (OA)

  • Unresponsive for at least 6 months to any two combinations of OA therapies:

    • Exercise, weight loss, physical therapy

    • Acetaminophen (Tylenol)

    • Topical or oral NSAIDs

    • IA injections

  • Other study requirements apply.

Participants may receive:

  • Compensation up to $1425

  • Study support and monitoring by a healthcare team

  • Diagnostic tests and procedures at no-cost

  • Access to a new possible therapy for people with knee osteoarthritis (OA)

  • May provide new information about the effects of PPS on knee OA pain

  • Some participants will receive placebo, which will have no effect on their condition.

Get started today.

You are not committed to participate in a study by completing this form. Participation is voluntary, and you may leave at any time if you change your mind.

What is osteoarthritis (OA)?

Illustration of a human knee joint showing vascular changes, cartilage degeneration, inflammation, and pain related to joint disease.

Osteoarthritis is a chronic disease of the whole joint, leading to and perpetuating inflammation, cartilage degeneration, vascular changes and pain.

Pharmacological treatment options for OA include pain medications, including topical and oral NSAIDs, and intra-articular injections. Although no longer recommended, many patients progress to opioids if earlier steps do not reduce the pain sufficiently.

None of the medications currently available to treat OA address the underlying disease pathology; they do not prevent, stop or restrain progression of OA.

Recognizing the pressing need for new, safe, and effective treatments for the symptoms and underlying disease pathology of OA, Paradigm is developing PPS for OA under the trademark, Zilosul®.

Information and image provided by: https://paradigmbiopharma.com/product-development/osteoarthritis-oa/